ArticleTranslational cancer research2025
Development of a mitochondrial permeability transition-driven necrosis-linked lncRNA signature for forecasting prognosis and treatment of lung adenocarcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is a common malignancy with a poor prognosis due to its aggressive nature and metastatic potential. Mitochondrial permeability transition (MPT)-driven necrosis and long non-coding RNAs (lncRNAs) play crucial roles in cancer progression. This study aimed to build a MPT-driven necrosis-linked lncRNA signature for forecasting prognosis and treatment of LUAD. Methods: The publicly available data of LUAD were downloaded from The Cancer Genome Atlas (TCGA) database for investigating the key MPT-driven necrosis-related lncRNAs in LUAD. Then, an MPT-driven necrosis-related lncRNA signature was constructed and its predictive performance for forecasting LUAD prognosis was examined. Moreover, nomogram construction, pathway, immune infiltration, immunotherapy response, and drug sensitivity analyses were performed to explore the clinical value and potential mechanisms of the signature in LUAD. Results: Six MPT-driven necrosis-related lncRNAs that were linked with LUAD prognosis were identified, including Conclusions: The six-MPT-driven necrosis-related lncRNA signature may be a powerful biomarker for forecasting prognosis and immunotherapy response of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.